comparemela.com

Fang Jianmin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center

United statesFang jianminLiu yutaoAmerican society of clinical oncology annual meetingChinese academy of medical sciences cancer hospitalPrnewswire remegen co ltdRemegen coRemegen co ltdAmerican societyClinical oncology annual meetingProfessor liu yutaoChinese academyMedical sciences cancer hospital

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical.

Czech republicUnited statesFang jianminGuo junRemegen coPrnewswire remegen co ltdRemegen co ltdAmerican society of clinical oncologyNational medical products administrationSeagen incUniversity cancer hospitalAmerican societyClinical oncologyAnnual meetingObjective response rateComplete response

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on.

United statesCzech republicFang jianminGuo junRemegen coUniversity cancer hospitalAmerican society of clinical oncologyPrnewswire remegen co ltdAmerican societyClinical oncologyAnnual meetingObjective response rateComplete responseDisease control rateProgression free survivalOverall survival

RemeGen Celebrates World Intellectual Property Day 2023

RemeGen Celebrates World Intellectual Property Day 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFang jianminRemegen coPrnewswire remegen co ltdRemegen co ltdWorld intellectual property dayChief scientific officerPatent management systemBusiness secret management

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

/PRNewswire/ RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin.

United statesDisitamab vedotinFang jianminAmerican society of clinical oncologyDrug administrationRemegen coPrnewswire remegen co ltdSeagen incRemegen co ltdNational medical products administrationChinese society of clinical oncologyClinical oncologyAnnual meetingLocally advancedMetastatic urothelial carcinomaCancers symposium

vimarsana © 2020. All Rights Reserved.